Parnell Pharmaceuticals Holdings Ltd
OTC:PARNF
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Parnell Pharmaceuticals Holdings Ltd
Inventory
Parnell Pharmaceuticals Holdings Ltd
Inventory Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Inventory | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Parnell Pharmaceuticals Holdings Ltd
OTC:PARNF
|
Inventory
AU$3.4m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Recce Pharmaceuticals Ltd
ASX:RCE
|
Inventory
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Mayne Pharma Group Ltd
ASX:MYX
|
Inventory
AU$50.6m
|
CAGR 3-Years
-23%
|
CAGR 5-Years
-12%
|
CAGR 10-Years
N/A
|
|
|
Neuren Pharmaceuticals Ltd
ASX:NEU
|
Inventory
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
C
|
Clarity Pharmaceuticals Ltd
ASX:CU6
|
Inventory
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Vita Life Sciences Ltd
ASX:VLS
|
Inventory
AU$15.1m
|
CAGR 3-Years
-1%
|
CAGR 5-Years
16%
|
CAGR 10-Years
9%
|
|
Parnell Pharmaceuticals Holdings Ltd
Glance View
Parnell Pharmaceuticals Holdings Ltd. operates as a veterinary pharmaceutical company. The company is headquartered in Alexandria, New South Wales. The company went IPO on 2014-06-18. The firm is focused on developing, manufacturing and commercializing animal health solutions. The principal activities of the Company include manufacture for global sale of animal pharmaceutical product, and research and development of pharmaceutical products for global animal health markets. The firm operates through four segments: Companion Animal, Production Animal-U.S., Production Animal-Rest of World and Manufacturing Operations. The company augments its pharmaceutical products with its FETCH and mySYNCH software platforms. The company offers disease-modifying product, Zydax, for the treatment of osteoarthritis (OA). Its reproductive hormone products include estroPLAN and GONAbreed. The company has a nutraceutical product, Glyde. The company also markets a non-steroidal anti-inflammatory drug (NSAID), called Tergive. The company is developing a pipeline of clinical drug candidates, such as PAR 121, PAR 122, PAR 101, PAR 081 and PAR 061.
See Also
What is Parnell Pharmaceuticals Holdings Ltd's Inventory?
Inventory
3.4m
AUD
Based on the financial report for Dec 31, 2015, Parnell Pharmaceuticals Holdings Ltd's Inventory amounts to 3.4m AUD.
What is Parnell Pharmaceuticals Holdings Ltd's Inventory growth rate?
Inventory CAGR 1Y
24%
Over the last year, the Inventory growth was 24%.
